Fresenius Kabi Taiwan Ltd.

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Activity

Key Events

Sep 4, 2026TrialEvaluation of Safety and Efficacy of Three Flavors of Supportan® Drink in Cancer Patients in Taiwan

Sep 1, 2026TrialSuitability of Two Flavours of a High-energy, Low-protein Formula (Renalive® LP) in Chronic Kidney Disease Stage 3b-5 Outpatients in Taiwan

Jul 28, 2026FDAGlycophos — GLYCOPHOS

Mar 14, 2025FDATYENNE — TYENNE

Mar 5, 2024FDATYENNE — TYENNE

Mar 15, 2022FDAAtropen — ATROPINE SULFATE

Nov 20, 2020FDAAtropen — ATROPEN

Sep 29, 2020FDAAtropen — ATROPINE SULFATE

2 more events

Jul 9, 2018FDAAtropen — ATROPINE (AUTOINJECTOR)

Jan 26, 2018FDAAtropen — ATROPINE SULFATE

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

1 patent group across drugs · Source: FDA Orange Book

DrugExpires

CancidasDec 21, 2032

Regulatory

Regulatory Timeline

20023 events

FDAJun 28

Atropen — ATROPEN

Application NDA017106

FDAMar 4

Atropen — ATROPEN

Application NDA017106

FDAJan 7

Atropen — ATROPEN

Application NDA017106

20031 event

FDAJun 19

Atropen — ATROPEN

Application NDA017106

20042 events

FDASep 17

Atropen — ATROPEN

Application NDA017106 (NDA)

FDASep 17

Atropen — ATROPEN

Application NDA017106

20131 event

FDANov 14

Atropen — ATROPEN

Application NDA017106

20141 event

FDAJul 18

Atropen — ATROPINE SULFATE

Application NDA206289 (NDA)

20151 event

FDAAug 10

Atropen — ATROPEN

Application NDA017106

20163 events

FDADec 30

Cancidas — CASPOFUNGIN ACETATE

Application NDA206110 (NDA)

FDADec 1

Atropen — ISOPTO ATROPINE

Application NDA208151 (NDA)

FDAMay 27

Atropen — ATROPEN

Application NDA017106

20182 events

FDAJul 9

Atropen — ATROPINE (AUTOINJECTOR)

Application NDA212319 (NDA)

FDAJan 26

Atropen — ATROPINE SULFATE

Application NDA209260 (NDA)

20202 events

FDANov 20

Atropen — ATROPEN

Application NDA017106

FDASep 29

Atropen — ATROPINE SULFATE

Application NDA214652 (NDA)

20221 event

FDAMar 15

Atropen — ATROPINE SULFATE

Application NDA213581 (NDA)

20241 event

FDAMar 5

TYENNE — TYENNE

Application BLA761275 (BLA)

20251 event

FDAMar 14

TYENNE — TYENNE

Application BLA761449 (BLA)

20261 event

FDAJul 28

Glycophos — GLYCOPHOS

Application NDA220381 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)